Statement of Ownership (sc 13g)
September 10 2021 - 06:05AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange
Act of 1934
(Amendment No. )*
Viridian Therapeutics, Inc.
|
(Name of Issuer)
|
|
Common
Stock, $0.01 par value
|
(Title of Class of Securities)
|
92790C104
|
(CUSIP Number)
|
|
September 1, 2021
|
(Date of Event Which Requires Filing of This Statement)
|
Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:
☒ Rule
13d-1(b)
☐ Rule 13d-1(c)
☐ Rule 13d-1(d)
*The remainder of this cover page shall be filled out
for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover
page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP
No. 92790C104
|
1
|
NAMES
OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
TCG Crossover Management, LLC
|
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
|
(a)o
(b)o
|
3
|
SEC
USE ONLY
|
4
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
Delaware, United States
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH REPORTING
PERSON WITH:
|
5
|
SOLE
VOTING POWER
914,000
|
6
|
SHARED
VOTING POWER
0
|
7
|
SOLE
DISPOSITIVE POWER
914,000
|
8
|
SHARED
DISPOSITIVE POWER
0
|
9
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
914,000
|
10
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)
o
|
11
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.5%
|
12
|
TYPE
OF REPORTING PERSON (see instructions)
IA
|
|
|
|
|
|
Item 1(a).
|
Name of Issuer:
|
|
|
|
Viridian Therapeutics, Inc.
|
|
|
Item 1(b).
|
Address of Issuer’s Principal Executive Offices:
|
|
|
|
203 Crescent Street, Bldg. 17, Suite 102B
Waltham, Massachusetts 02453
|
|
|
Item 2(a).
|
Name of Person Filing:
|
|
|
|
TCG Crossover Management, LLC
|
|
|
Item 2(b).
|
Address of Principal Business Office or, if none, Residence:
|
|
|
|
228 Hamilton Avenue, 3rd Floor
Palo Alto, California
United States 94301
|
|
|
Item 2(c).
|
Citizenship:
|
|
|
|
The Investment Manager is a Delaware limited liability company.
|
|
|
Item 2(d).
|
Title of Class of Securities:
|
|
|
|
Common Stock, $0.01 par value
|
|
|
Item 2(e).
|
CUSIP Number:
92790C104
|
Item 3.
|
If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check
whether the person filing is a:
|
|
(a)
|
o
|
Broker or dealer registered under Section 15 of the Act;
|
|
(b)
|
o
|
Bank as defined in Section 3(a)(6) of the Act;
|
|
(c)
|
o
|
Insurance company as defined in Section 3(a)(19) of the Act;
|
|
(d)
|
o
|
Investment company registered under Section 8 of the Investment Company Act of 1940;
|
|
(e)
|
x
|
An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
|
|
(f)
|
o
|
An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
|
|
(g)
|
o
|
A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
|
|
(h)
|
o
|
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.
1813);
|
|
(i)
|
o
|
A church plan that is excluded from the definition of an investment company under section 3(c)(14)
of the Investment Company Act of 1940;
|
|
(j)
|
o
|
A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
|
|
(k)
|
o
|
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance
with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
|
Item 4.
|
Ownership.
|
|
|
Provide the following information regarding the aggregate
number and percentage of the class of securities of the issuer identified in Item 1.
TCG Crossover Management, LLC
|
|
(a)
|
Amount Beneficially Owned:
|
914,000
|
|
(b)
|
Percent of Class:
|
9.5%
|
|
(c)
|
Number of shares as to which such person has:
|
|
|
|
(i)
|
sole power to vote or to direct the vote:
|
914,000
|
|
|
(ii)
|
shared power to vote or to direct the vote:
|
0
|
|
|
(iii)
|
sole power to dispose or to direct the disposition of:
|
914,000
|
|
|
(iv)
|
shared power to dispose or to direct the disposition of:
|
0
|
Item 5.
|
Ownership of Five Percent or Less of a Class.
|
|
|
|
If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons
have ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.
|
|
|
Item 6.
|
Ownership of More than Five Percent on Behalf of Another Person.
|
|
|
|
Not applicable
|
|
|
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported
on by the Parent Holding Company.
|
|
|
|
Not applicable.
|
|
|
Item 8.
|
Identification and Classification of Members of the Group.
|
|
|
|
Not applicable.
|
|
|
Item 9.
|
Notice of Dissolution of Group.
|
|
|
|
Not applicable.
|
|
|
Item 10.
|
Certification.
|
|
|
|
By signing below I certify that, to the best of my knowledge and belief, the securities referred
to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of
and do not have the effect of changing the control of the issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having such purpose or effect for the time being.
|
SIGNATURE
After reasonable inquiry and
to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
September 9, 2021
|
|
|
Date
|
|
|
/s/ Jaime Felix
|
|
|
Signature
Chief Compliance Officer
|
|
|
Name/Title
|
|
6
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Mar 2023 to Mar 2024